Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Atorvastatin (Lipitor®) chewable tablets are recommended as an option for use within NHS Wales:
|
|||
|
|||
Medicine details |
|||
| Medicine name | atorvastatin (Lipitor®) | ||
| Formulation | 5 mg, 10 mg, 20 mg, 40 mg chewable tablet | ||
| Reference number | 1480 | ||
| Indication | As an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. To reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors |
||
| Company | Pfizer Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1112 | ||
| NMG meeting date | 28/03/2012 | ||
| AWMSG meeting date | 09/05/2012 | ||
| Ratification by Welsh Government | 18/06/2012 | ||
| Date of issue | 19/06/2012 | ||
| Date of last review | August 2022 | ||
| Further information This appraisal recommendation was reviewed in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||